Concepts represent early planning stages for program announcements, requests for applications, notices of special interest, or solicitations for Council’s input. If NIAID publishes an initiative from one of these concepts, we link to it below. To find initiatives, go to Opportunities & Announcements.
Note: Council approval does not guarantee that a concept will become an initiative.
Table of Contents
Fiscal Year (FY) 2026 Division of Allergy, Immunology, and Transplantation (DAIT) Concepts
- Asthma and Allergic Diseases Cooperative Research Centers
- CIVICs Data Management and Coordinating Center
- Molecular Mechanisms of Combination Adjuvants (MMCA)
- NIAID DAIT Clinical Products Center (CPC)
- Nonhuman Primate Reagent Resource
- Mucosal Immunology Studies Team (MIST)
- Notice of Special Interest (NOSI)—Accelerating Progress in Celiac Disease Research
- Notice of Special Interest (NOSI)—Leveraging Microbial Exposure for Improving Mouse Models of Human Immunity
- Notice of Special Interest (NOSI)—Somatic Cell Gene Editing Therapies to Improve Transplantation Outcomes
Asthma and Allergic Diseases Cooperative Research Centers
For the published request for applications, check the January 16, 2025 Guide announcement, Asthma and Allergic Diseases Cooperative Research Centers (U19, Clinical Trial Optional).
CIVICs Data Management and Coordinating Center
Request for Proposals—proposed FY 2026 initiative
Contact:
Maribel Miranda
[email protected]
Objective: To provide a data management and program coordination center for the Collaborative Influenza Vaccine Innovation Centers (CIVICs) network.
Description: The purpose of this renewal solicitation is to provide data management and program coordination services to the CIVICs network (Vaccine Centers and related Cores) in the areas of preclinical data and meta-data management services (studies include animal models and nonclinical trial human subjects research); development of harmonized data standards; and coordination of CIVICs network-related activities including cross-network communication and collaboration, CIVICs-wide meeting and webinar management, and tracking and distribution of CIVICs-generated reagents and other resources to CIVICs investigators and the broader research community.
Molecular Mechanisms of Combination Adjuvants (MMCA)
For the published request for applications, check the January 13, 2025 Guide announcement, Molecular Mechanisms of Combination Adjuvants (MMCA) (R01, Clinical Trial Not Allowed).
NIAID DAIT Clinical Products Center (CPC)
For the published request for proposals, check the October 18, 2024 solicitation, NIAID Clinical Products Center (CPC).
Nonhuman Primate Reagent Resource
For the published request for applications, check the September 4, 2025 Guide announcement, Nonhuman Primate Reagent Resource (U24, Clinical Trial Not Allowed).
Mucosal Immunology Studies Team (MIST)
For the published request for applications, check the August 27, 2025 Guide announcement, Mucosal Immunology Studies Team (MIST) (U01, Clinical Trial Not Allowed).
Notice of Special Interest (NOSI)—Accelerating Progress in Celiac Disease Research
Notice of Special Interest (NOSI)—proposed FY 2026 initiative
Contact:
Kelly Hudspeth
[email protected]
Objective: To inform potential applicants to NIH of special interest in research on the etiology and pathogenesis of celiac disease, identification of therapeutic targets, and development of preventative or disease ameliorating therapies/strategies.
Description: This NOSI will support investigations focused on gaining understanding of the immune basis of celiac disease, as follows:
- Determining mechanisms underlying loss of oral tolerance.
- Identifying triggers of autoimmunity in celiac disease.
- Evaluating strategies to eliminate and revert the pathogenic memory gluten-specific CD4 memory T cells.
- Defining the cellular circuits and mechanisms involved in tissue destruction.
- Identifying the role of microbiota in the loss of oral tolerance and tissue destruction.
- Finding immune modulating interventions and strategies to prevent celiac disease and/or restore tolerance.
- Identifying biomarkers to predict tissue destruction in celiac disease.
- Determining what makes gluten a harmful dietary antigen that can cause tissue destruction.
- Discovering what triggers development of inflammatory T helper-1 responses to a dietary antigen.
- Determining how tissue destruction is linked to loss of tolerance.
- Identifying pathogenic mechanisms shared between celiac disease and other complex immune disorders.
Notice of Special Interest (NOSI)—Leveraging Microbial Exposure for Improving Mouse Models of Human Immunity
For the published notice of special interest, check the November 20, 2024 Guide notice, Notice of Special Interest (NOSI) — Leveraging Microbial Exposure for Improving Mouse Models of Human Immunity.
Notice of Special Interest (NOSI)—Somatic Cell Gene Editing Therapies to Improve Transplantation Outcomes
For the published notice of special interest, check the December 3, 2024 Guide notice, Notice of Special Interest (NOSI): Somatic Cell Gene Editing Therapies to Improve Transplantation Outcomes.